Whitehawk Therapeutics (WHWK) AI Stock Analysis

• Market Cap: $85.30M
• Dividend Yield: N/A
• Average Volume (3M): 106.08K
• Price to Earnings (P/E): 12.0
• Beta (1Y): 0.49
• Revenue Growth: -9.33%
• EPS Growth: 97.60%
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 47,128,360
• 10 Day Avg. Volume: 148,248
• 30 Day Avg. Volume: 106,080
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.56
• Enterprise Value/Revenue: -2.22
• Enterprise Value/Gross Profit: 9.41
• Enterprise Value/Ebitda: 0.50
• 1Y Price Target: $2.00
• Price Target Upside: 10.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 44 Neutral
• Price Target: $2.00 ▲(10.50% Upside)

Whitehawk Therapeutics' overall stock score is primarily impacted by its financial performance, which is the most significant factor due to ongoing losses and negative cash flows. Technical analysis shows mixed signals with short-term positive momentum but potential overbought conditions. The valuation is weak, with a negative P/E ratio and no dividend yield, further contributing to the low score.

Positive Factors

Financial Stability

Whitehawk ended with $177.2M in cash, providing an operational runway into 2028.

Pipeline Progress

Upcoming catalysts include IND submissions for key drug candidates, which could lead to further developments.

Strategic Developments

Whitehawk Therapeutics is taking a swift and strategic approach to developing an innovative portfolio of ADCs.

Negative Factors

Financial Performance

Whitehawk recorded a net loss of $0.76 per share vs. the previously estimated net loss of $0.17 per share.

Market Risks

Risks include disappointing market uptake of FYARRO and potential medium- to long-term dilution risk.

Operational Costs

R&D and SG&A expenses were significantly higher than estimates, indicating increased operational costs.

Whitehawk Therapeutics Business Overview & Revenue Model

Company Description

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

How the Company Makes Money

Whitehawk Therapeutics generates revenue through a combination of research and development funding, partnerships, and licensing agreements with larger pharmaceutical companies. The company typically enters into collaborations to co-develop its drug candidates, which can include upfront payments, milestone payments based on developmental progress, and royalties on future product sales. Additionally, Whitehawk may receive grants or funding from governmental and non-governmental organizations aimed at advancing medical research, which further supports its financial structure. The strategic partnerships enhance its research capabilities and expand its market reach, contributing significantly to its revenue streams.

Whitehawk Therapeutics Financial Statement Overview

Summary

Whitehawk Therapeutics is facing financial challenges with persistent losses and negative cash flows, despite some revenue growth. Profitability metrics are concerning, and the company needs to improve its cost structure and operational efficiency. The balance sheet is strong with low leverage, but the lack of profitability and cash flow generation are critical areas needing attention.

Income Statement

Whitehawk Therapeutics has shown a consistent increase in revenue over the years, with a revenue growth rate of 6.7% from 2023 to 2024. However, the company is struggling with negative gross profit margins and net profit margins, indicating that costs are significantly outweighing revenue. The EBIT and EBITDA margins are also negative, reflecting ongoing operational losses. These factors suggest financial instability and a need for strategic adjustments to improve profitability.

Balance Sheet

The company's balance sheet shows a strong equity position with a high equity ratio of 74.6% in 2024, indicating financial stability in terms of asset financing. However, the debt-to-equity ratio is low at 0.02, suggesting minimal leverage, which can be a double-edged sword in terms of growth potential. The return on equity is negative due to ongoing net losses, highlighting the challenge of generating returns for shareholders.

Cash Flow

Whitehawk Therapeutics is experiencing negative free cash flow, although there was a slight improvement from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its net losses. The free cash flow to net income ratio is also negative, underscoring the company's cash flow challenges and the need for improved cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.60M	25.98M	24.35M	15.22M	1.12M	14.58M
Gross Profit	-5.10M	-28.07M	-27.38M	-18.78M	-18.55M	-428.00K
EBITDA	-96.72M	-64.63M	-71.76M	-58.80M	-36.96M	-2.54M
Net Income	-10.42M	-63.69M	-65.77M	-60.51M	-110.09M	-3.48M
Balance Sheet
Total Assets	180.82M	70.32M	132.42M	184.24M	157.91M	18.82M
Cash, Cash Equivalents and Short-Term Investments	177.20M	47.24M	108.84M	172.56M	148.99M	4.46M
Total Debt	0.00	833.00K	1.27M	1.66M	605.00K	10.26M
Total Liabilities	8.76M	17.84M	27.23M	25.86M	21.50M	31.26M
Stockholders Equity	172.07M	52.48M	105.19M	158.38M	136.41M	-12.43M
Cash Flow
Free Cash Flow	-96.49M	-61.20M	-63.63M	-50.08M	-22.47M	-12.70M
Operating Cash Flow	-95.56M	-59.55M	-59.66M	-49.64M	-22.42M	-12.70M
Investing Cash Flow	104.89M	25.20M	83.21M	-132.89M	25.15M	0.00
Financing Cash Flow	94.40M	130.00K	326.00K	72.62M	141.80M	1.19M

Whitehawk Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.81
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Positive. The current price of 1.81 is above the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.84, and below the 200-day MA of 2.15, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 55.33 is Neutral, neither overbought nor oversold. The STOCH value of 73.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WHWK.

Whitehawk Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGNX	52 Neutral	$114.40M	―	-69.71%	―	303.47%	73.70%
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
VERU	47 Neutral	$50.86M	―	-96.35%	―	-52.76%	43.40%
WHWK	44 Neutral	$85.30M	12.00	-8.31%	―	-9.33%	97.60%
SRZN	43 Neutral	$95.13M	―	-130.27%	―	―	35.81%
TNYA	36 Underperform	$176.01M	―	-85.21%	―	―	38.94%
BDTX	33 Underperform	$165.11M	12.25	11.85%	―	―	―

Whitehawk Therapeutics Corporate Events

Whitehawk Therapeutics Elects Directors at Annual Meeting

Whitehawk Therapeutics, Inc. held its annual meeting of stockholders on June 11, 2025, where 61% of the voting power was represented. During the meeting, three Class II directors were elected, executive compensation was approved on an advisory basis, and BDO USA, P.C. was ratified as the independent accounting firm for the fiscal year ending December 31, 2025.